EC approves Otsuka and Astex’s Inaqovi for acute myeloid leukaemia

19 Sep 2023
www.pmlive.com
Drug ApprovalClinical ResultClinical Study
EC approves Otsuka and Astex’s Inaqovi for acute myeloid leukaemia
Preview
Source: PMLiVE
The European Commission (EC) has approved Otsuka Pharmaceutical and Astex Pharmaceuticals’s Inaqovi (oral decitabine and cedazuridine) as a monotherapy in certain acute myeloid leukaemia (AML) patients.
The EC’s decision, which specifically applies to adults with newly diagnosed AML who are ineligible for standard induction chemotherapy, makes Inaqovi the first oral hypomethylating agent approved in the European Economic Area for this patient population.
AML is a rapidly progressing cancer of the blood and bone marrow and the most common form of acute leukaemia in adults. Within Europe, the incidence of AML is increasing, rising from 3.48 per 100,000 population in 1976 to 5.06 in 2013.
Current treatment options for adults with AML range from hospital-administered intravenous (IV) chemotherapy infusions or, for those who are unable to receive chemotherapy, regimens based on parenterally administered hypomethylating agents.
By inhibiting cytidine deaminase in the gut and liver, Otsuka and Astex’s decitabine and cedazuridine fixed-dose combination is designed to allow for oral daily administration of decitabine over five days in a given cycle to achieve comparable systemic exposure to IV decitabine administered with the same dosing regimen.
The EC’s approval is supported by results from the late-stage ASCERTAIN trial, in which the fixed-dose combination demonstrated pharmacokinetic exposure equivalence to a standard five-day regimen of IV decitabine.
In addition to the EC approval, the European Medicines Agency previously agreed to a paediatric investigation plan for the oral combination treatment, which the partners say represents “an important milestone for the prospect of furthering clinical studies in children with AML”.
A paediatric investigation plan is a development plan aimed at ensuring that the necessary data is obtained through studies of children to support the authorisation of a medicine for this demographic in Europe.
The EC approval comes just over a month after Astex and MSD – known as Merck & Co in the US and Canada – expanded their drug discovery collaboration with the goal of identifying small-molecule candidates with activity towards a tumour suppressor protein.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.